It is safe to say that in the life sciences regulatory world, 2016 was the year of the price increase, as leading industry players experienced significant public outrage over what appeared to be extreme price increases.
What is compliance’s role when it comes to price increases? Does the ethics and compliance function get to weigh in on how decisions to raise the prices of products are reached, or does this function lie solely with the business?
Mark Scallon, FRA partner and director of the firm’s life sciences practice and Derek Patterson, FRA Principal explore these increasingly important questions.
Read their commentary in Life Science Compliance.
Author: Mark Scallon, FRA partner
FRA Life Sciences
FRA Life Sciences provides a broad set of services to help companies identify global compliance risk as well as develop practical, yet effective, solutions for operating under increasing scrutiny. Our expertise will help mitigate global compliance risk across multiple functional areas, including sales and marketing, medical affairs, research & development and instill any necessary change in a company’s compliance culture.